$XERS
Xeris Biopharma Holdings, Inc. Stock $xers

$xers Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000186709622000040 Filed on March 11, 2022

Income Statement

Concept	2021 Q4	2021	2020 Q4
Revenue	$21.43M	$49.59M	$7.170M
YoY Change	198.87%	142.67%	291.8%
Cost Of Revenue	$4.889M	$13.32M	$3.410M
YoY Change	43.37%	42.74%	117.2%
Gross Profit	$16.54M	$36.27M	$3.770M
YoY Change	338.73%	226.48%	1350.0%
Gross Profit Margin	77.19%	73.14%	52.58%
Selling, General & Admin	$51.98M	$125.7M	$18.00M
YoY Change	188.77%	70.51%	-12.79%
% of Gross Profit	314.26%	346.6%	477.45%
Research & Development	$10.08M	$25.16M	$5.110M
YoY Change	97.3%	20.26%	-58.86%
% of Gross Profit	60.96%	69.36%	135.54%
Depreciation & Amortization	$899.0K	$1.329M	$450.0K
YoY Change	99.78%	-9.41%	18.42%
% of Gross Profit	5.44%	3.66%	11.94%
Operating Expenses	$62.61M	$150.9M	$23.11M
YoY Change	170.93%	59.4%	-30.1%
Operating Profit	-$46.07M	-$115.2M	-$19.34M
YoY Change	138.22%	37.84%	-41.04%
Interest Expense	-$1.726M	$7.200M	-$2.570M
YoY Change	-32.84%	-32.71%	188.76%
% of Operating Profit
Other Income/Expense, Net	-$793.0K	-$7.569M	$60.00K
YoY Change	-1421.67%	-1.75%	-60.0%
Pretax Income	-$50.79M	-$122.7M	-$21.86M
YoY Change	132.34%	34.49%	-34.82%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$50.79M	-$122.7M	-$21.86M
YoY Change	132.34%	34.66%	-33.92%
Net Earnings / Revenue	-237.02%	-247.48%	-304.88%
Basic Earnings Per Share		-$1.55
Diluted Earnings Per Share	-$416.5K	-$1.553M	-$408.0K
COMMON SHARES
Basic Shares Outstanding	124.7M shares	79.03M shares
Diluted Shares Outstanding		79.03M shares

Balance Sheet

Concept	2021 Q4	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$102.4M	$102.4M	$133.8M
YoY Change	-23.44%	-23.44%	77.22%
Cash & Equivalents	$67.27M	$67.27M	$37.60M
Short-Term Investments	$35.16M	$35.16M	$96.20M
Other Short-Term Assets	$4.589M	$4.589M	$3.200M
YoY Change	43.41%	43.41%	-21.95%
Inventory	$18.12M	$18.12M	$8.353M
Prepaid Expenses	$4.589M		$3.196M
Receivables	$17.46M	$17.46M	$6.875M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$142.6M	$142.6M	$152.2M
YoY Change	-6.32%	-6.31%	73.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.627M	$6.627M	$6.707M
YoY Change	-1.19%	-1.09%	-15.1%
Goodwill	$22.86M		$0.00
YoY Change
Intangibles	$131.5M		$0.00
YoY Change
Long-Term Investments			$0.00
YoY Change			-100.0%
Other Assets	$829.0K	$829.0K	$232.0K
YoY Change	257.33%	314.5%	-42.0%
Total Long-Term Assets	$161.8M	$161.8M	$6.939M
YoY Change	2231.24%	2210.93%	-67.73%
TOTAL ASSETS
Total Short-Term Assets	$142.6M	$142.6M	$152.2M
Total Long-Term Assets	$161.8M	$161.8M	$6.939M
Total Assets	$304.4M	$304.4M	$159.2M
YoY Change	91.24%	91.18%	46.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.924M	$8.924M	$3.117M
YoY Change	186.3%	187.87%	-44.34%
Accrued Expenses	$49.09M	$68.13M	$15.90M
YoY Change	208.83%	174.71%	-26.07%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$79.04M	$79.04M	$28.21M
YoY Change	180.21%	180.28%	3.32%
LONG-TERM LIABILITIES
Long-Term Debt	$88.07M	$88.07M	$87.00M
YoY Change	1.23%	1.23%	49.23%
Other Long-Term Liabilities	$1.676M	$37.08M	$3.533M
YoY Change	-52.56%	263.54%	-60.3%
Total Long-Term Liabilities	$1.676M	$125.1M	$3.533M
YoY Change	-52.56%	28.75%	-94.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$79.04M	$79.04M	$28.21M
Total Long-Term Liabilities	$1.676M	$125.1M	$3.533M
Total Liabilities	$209.1M	$209.1M	$125.4M
YoY Change	66.78%	66.77%	32.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$460.1M		-$337.4M
YoY Change	36.38%
Common Stock	$13.00K		$6.000K
YoY Change	116.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$95.23M	$95.23M	$33.76M
YoY Change
Total Liabilities & Shareholders Equity	$304.4M	$304.4M	$159.2M
YoY Change	91.24%	91.18%	46.01%

Cashflow Statement

Concept	2021 Q4	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$50.79M	-$122.7M	-$21.86M
YoY Change	132.34%	34.66%	-33.92%
Depreciation, Depletion And Amortization	$899.0K	$1.329M	$450.0K
YoY Change	99.78%	-9.41%	18.42%
Cash From Operating Activities	-$28.95M	-$95.54M	-$10.87M
YoY Change	166.29%	18.59%	-63.25%
INVESTING ACTIVITIES
Capital Expenditures	-$131.0K	$1.085M	-$230.0K
YoY Change	-43.04%	187.8%	-8.0%
Acquisitions
YoY Change
Other Investing Activities	$36.73M	$99.05M	$7.470M
YoY Change	391.74%	-466.44%	-184.89%
Cash From Investing Activities	$36.60M	$97.96M	$7.240M
YoY Change	405.55%	-457.47%	-180.09%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$27.00M
YoY Change		-59.02%
Debt Paid & Issued, Net		$0.00
YoY Change		-100.0%
Cash From Financing Activities	125.0K	$27.25M	3.320M
YoY Change	-96.23%	-78.39%	68.53%
NET CHANGE
Cash From Operating Activities	-28.95M	-$95.54M	-10.87M
Cash From Investing Activities	36.60M	$97.96M	7.240M
Cash From Financing Activities	125.0K	$27.25M	3.320M
Net Change In Cash	7.781M	$29.68M	-310.0K
YoY Change	-2610.0%	63.95%	-99.15%
FREE CASH FLOW
Cash From Operating Activities	-$28.95M	-$95.54M	-$10.87M
Capital Expenditures	-$131.0K	$1.085M	-$230.0K
Free Cash Flow	-$28.81M	-$96.62M	-$10.64M
YoY Change	170.82%	19.38%	-63.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001867096
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-40880
CY2021	dei	Entity Registrant Name EntityRegistrantName	XERIS BIOPHARMA HOLDINGS, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-1082097
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	180 N. LaSalle Street
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1600
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Chicago
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60601
CY2021	dei	City Area Code CityAreaCode	844
CY2021	dei	Local Phone Number LocalPhoneNumber	445-5704
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	XERS
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	266000000.0	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	135523511	shares
CY2021	dei	Auditor Name AuditorName	KPMG LLP
CY2021	dei	Auditor Location AuditorLocation	Chicago, Illinois
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67271000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37598000	USD
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	35162000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	96190000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17456000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6875000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	18118000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	8353000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4589000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3196000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	142596000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	152212000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6627000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6707000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	22859000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	0	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	131450000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	829000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	232000	USD
CY2021Q4	us-gaap	Assets Assets	304361000	USD
CY2020Q4	us-gaap	Assets Assets	159151000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8924000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3117000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49088000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15895000	USD
CY2021Q4	xers	Accrual For Rebates And Trade Discounts AccrualForRebatesAndTradeDiscounts	15041000	USD
CY2020Q4	xers	Accrual For Rebates And Trade Discounts AccrualForRebatesAndTradeDiscounts	5984000	USD
CY2021Q4	xers	Accruedreturnsreserve Accruedreturnsreserve	4000000	USD
CY2020Q4	xers	Accruedreturnsreserve Accruedreturnsreserve	2889000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1987000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	322000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	79040000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	28207000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	88067000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	87021000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	22531000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2021Q4	xers	Supply Agreements Liability Noncurrent SupplyAgreementsLiabilityNoncurrent	5991000	USD
CY2020Q4	xers	Supply Agreements Liability Noncurrent SupplyAgreementsLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6883000	USD
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	6629000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4942000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1676000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3533000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	209130000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	125390000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	124873316	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	59611202	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	13000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	555359000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	371134000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-460110000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-337385000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	95231000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	33761000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	304361000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	159151000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	49280000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20155000	USD
CY2021	xers	Grantincome Grantincome	310000	USD
CY2020	xers	Grantincome Grantincome	280000	USD
CY2021	us-gaap	Revenues Revenues	49590000	USD
CY2020	us-gaap	Revenues Revenues	20435000	USD
CY2021	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	13318000	USD
CY2020	us-gaap	Cost Of Goods And Service Excluding Depreciation Depletion And Amortization CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization	9328000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25160000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20921000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	125718000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	73732000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	550000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2021	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	164746000	USD
CY2020	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	103981000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-115156000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-83546000	USD
CY2021	us-gaap	Interest Income Other InterestIncomeOther	313000	USD
CY2020	us-gaap	Interest Income Other InterestIncomeOther	2965000	USD
CY2021	us-gaap	Interest Expense InterestExpense	7180000	USD
CY2020	us-gaap	Interest Expense InterestExpense	10660000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	702000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	9000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7569000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7704000	USD
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-122725000	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-91250000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-110000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-122725000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-91140000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-38000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-10000	USD
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-27000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-122762000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-91177000	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.55
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.14
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	79027062	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42642901	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	14436000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-91140000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	61514000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	39937000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	172000	USD
CY2020	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	63000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8273000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	669000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-37000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	33761000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-122725000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	26925000	USD
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	137655000	USD
CY2021	xers	Adjustments To Additional Paid In Capital Equity Issued For Transactions AdjustmentsToAdditionalPaidInCapitalEquityIssuedForTransactions	7964000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	199000	USD
CY2021	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	534000	USD
CY2021	xers	Stock Issued During Period Value Vesting Of Restricted Stock Units StockIssuedDuringPeriodValueVestingOfRestrictedStockUnits	534000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11381000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	642000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-37000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	95231000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-122725000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-91140000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1329000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1467000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	550000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2021	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-413000	USD
CY2020	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-84000	USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	961000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	980000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	11381000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	8273000	USD
CY2021	xers	Gain Loss On Conversion Of Debt GainLossOnConversionOfDebt	0	USD
CY2020	xers	Gain Loss On Conversion Of Debt GainLossOnConversionOfDebt	2124000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-443000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	702000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	9000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6237000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2182000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-3290000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-925000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7418000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5143000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5527000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2486000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	12556000	USD
CY2020	xers	Accruedtradediscountsandrebates Accruedtradediscountsandrebates	4609000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2207000	USD
CY2021	xers	Accruedtradediscountsandrebates Accruedtradediscountsandrebates	4213000	USD
CY2021	xers	Increaseinaccruedreturnsreserve Increaseinaccruedreturnsreserve	1110000	USD
CY2020	xers	Increaseinaccruedreturnsreserve Increaseinaccruedreturnsreserve	932000	USD
CY2021	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	254000	USD
CY2020	us-gaap	Increase Decrease In Deferred Liabilities IncreaseDecreaseInDeferredLiabilities	-447000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1441000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	3201000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-95535000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-80558000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1085000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	377000	USD
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	43020000	USD
CY2020	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	101773000	USD
CY2021	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	103600000	USD
CY2020	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	74745000	USD
CY2021	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	38469000	USD
CY2020	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	27000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	97964000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27405000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	65891000	USD
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	54000	USD
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4315000	USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	94839000	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	25089000	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	5603000	USD
CY2021	xers	Payments For Debt Conversion Costs PaymentsForDebtConversionCosts	0	USD
CY2020	xers	Payments For Debt Conversion Costs PaymentsForDebtConversionCosts	400000	USD
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	642000	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	669000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	193000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	135000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	534000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	63000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27247000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	126064000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-3000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-22000	USD
CY2021	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	29673000	USD
CY2020	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	18079000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37598000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19519000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	67271000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37598000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	7294000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	4555000	USD
CY2021	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	37812000	USD
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2020	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	347000	USD
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	137655000	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	USD
CY2021	xers	Noncash Or Part Noncash Acquisition Equity Assumed NoncashOrPartNoncashAcquisitionEquityAssumed	8871000	USD
CY2020	xers	Noncash Or Part Noncash Acquisition Equity Assumed NoncashOrPartNoncashAcquisitionEquityAssumed	0	USD
CY2021	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	22531000	USD
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Debt Assumed1 NoncashOrPartNoncashAcquisitionDebtAssumed1	0	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Organization and nature of the business <div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of business </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Xeris Biopharma Holdings, Inc. ("Xeris Biopharma" or the "Company") is a biopharmaceutical company committed to developing and commercializing innovative solutions to enhance the lives of people with life-threatening diseases. The Company's primary focus is on therapies for patient populations in endocrinology, neurology, and gastroenterology. The Company currently has three commercially available products, Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first and only U.S. Food and Drug Administration (“FDA”) approved therapy for primary periodic paralysis (“PPP”), and Recorlev, approved by the FDA in December 2021 for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s Syndrome. The Company also has a pipeline of development programs to extend the current marketed products into new indications and uses or bring new products forward using the proprietary formulation technology platforms, XeriSol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and XeriJect</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On October 5, 2021, Xeris Pharmaceuticals, Inc. ("Xeris Pharma") acquired Strongbridge Biopharma plc (“Strongbridge”), a biopharmaceutical company commercializing therapies for rare diseases with significant unmet needs. Immediately following the acquisition and related transactions, both Xeris Pharma and Strongbridge became wholly owned subsidiaries of Xeris Biopharma. The common stock of Xeris Pharma and the ordinary shares of Strongbridge were de-registered after completion of the Transactions. On October 6, 2021, Xeris Biopharma’s common stock, par value $0.0001 per share, commenced trading on the Nasdaq Global Select Market (“Nasdaq”) under the ticker symbol “XERS”. See “Note 3 – Business combination” for a more detailed description of the acquisition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As used herein, the “Company” or "Xeris" refers to Xeris Pharma when referring to periods prior to the acquisition of Strongbridge, an Irish public limited company, on October 5, 2021 and to Xeris Biopharma when referring to periods on or subsequent to October 5, 2021. As a result, Xeris Pharma became the predecessor to Xeris Biopharma Holdings, Inc. upon completion of the Merger on October 5, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Liquidity and capital resources</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has incurred operating losses since inception and has an accumulated deficit of $460.1 million as of December 31, 2021. The Company expects to continue to incur net losses for at least the next 12 months beyond the issuance date of these consolidated financials. Based on the Company’s current operating plans, existing working capital at December 31, 2021, and capital raised after year-end (refer to Note 19), the Company believes the cash resources are sufficient to sustain operations and capital expenditure requirements for at least the next 12 months from the issuance date of these consolidated financial statements. If needed, the Company may elect to finance the operations through equity or debt financing along with revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There can be no assurance that such funding may be available to the Company on acceptable terms, or at all, or that the Company will be able to successfully market and sell Gvoke, Keveyis and Recorlev. Market volatility resulting from the COVID-19 pandemic or other factors could also adversely impact the Company's ability to access capital as and when needed. The issuance of equity securities may result in dilution to stockholders. If the Company raises additional funds through the issuance of additional debt, which may have rights, preferences and privileges senior to those of our common stockholders, the terms of the debt could impose significant restrictions on the operations. The failure to raise funds as and when needed could have a negative impact on the Company's financial condition and ability to pursue the business strategies. If additional funding is not secured when required, the Company may need to delay or curtail the operations until such funding is received, which would have a material adverse impact on the business prospects and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Significant risks</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other specialty pharmaceutical companies, including, but not limited to, successful commercialization and market acceptance of available products and any future products, if and when approved, successful development of the product candidates, the development of new technological innovations by competitors, and protection of intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing global outbreak of the coronavirus disease (“COVID-19”) has resulted in significant governmental measures being implemented to control the spread of the virus and has caused the Company to modify the business practices (including remote work for most of the employees from time to time). While the Company cannot predict the scope and severity, these developments and measures could materially and adversely affect the business, results of operations and financial condition. The Company is continuing to closely monitor the impact of the COVID-19 pandemic on all aspects of the business and is taking steps to minimize the impact on the business. However, the extent to which COVID-19 impacts the business, results of operations or financial condition will depend on the extent and severity of the continued spread of COVID-19 globally, the effectiveness of actions taken to contain the pandemic or treat its impact, and the resulting economic consequences, among others. Furthermore, if the Company or any of the third parties with whom the Company engages were to experience shutdowns or other business disruptions, the Company's ability to conduct the </span></div>business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on the business, results of operations and financial condition.
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-460100000	USD
CY2021	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the guidance in ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to all contracts with customers within the scope of the standard. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company sells product primarily to wholesalers or a specialty pharmacy who subsequently resell to retail pharmacies or patients. The Company enters into arrangements with payors, group purchasing organizations, and healthcare providers that provide for government-mandated or privately-negotiated rebates, chargebacks and discounts related to the Company’s products. The Company currently sells Gvoke, Keveyis and Recorlev in the United States only and Ogulo (European brand name of Gvoke) in the United Kingdom. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenue is recognized when the Company's customer (e.g., a wholesaler or specialty pharmacy) obtains control of promised goods or services, which is when the Company's obligations under the terms of the contract with the customer are satisfied, based on the consideration the Company expects to receive in exchange for those goods or services. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Revenues are recorded at the net product sales price, which includes estimated allowances for patient copay assistance programs, prompt payment discounts, payor rebates, chargebacks, service fees, and product returns, all of which are recorded at the time of sale to the pharmaceutical wholesaler or other customer. The Company applies significant judgments and estimates in determining some of these allowances. If actual results differ from its estimates, adjustments are made to these allowances in the period in which the actual results or updates to estimates become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Patient Copay Assistance Program</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company offers savings programs to commercially insured patients under which the cost of a prescription to a patient is discounted. The Company reimburses pharmacies for this discount through a third-party vendor. The Company records an accrual to reduce gross sales for the estimated copay on units sold to wholesalers and other customers. The estimate is based on estimated percentages of products that will be prescribed to qualified patients, expected patient utilization of the discount program, average assistance paid based on reporting from the third-party vendor as well as industry data and estimated levels of inventory in the distribution channel. Accrued copay fees are recorded as a reduction of product revenues and included in accrued trade discounts and rebates on the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Rebates</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company contracts with certain private payor organizations, primarily insurance companies and pharmacy benefit managers, to provide rebates with respect to utilization of the products and contracted formulary status. The Company accrues estimated rebates based on actual average rebate amounts and estimated percent of product that will be prescribed to qualified patients and records the rebate as a reduction of product revenues. Accrued commercial rebates are included in accrued trade discounts and rebates on the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Government Rebates</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company participates in certain federal and state government rebate programs such as the Medicaid Drug Rebate Program, TRICARE Retail Refunds Program, and Medicare Part D Program. The Company accrues estimated rebates and discounts based on actual average rebate amounts and estimated percent of product that will be prescribed to qualified patients and records the rebates as a reduction of product revenues. Accrued government rebates are included in accrued trade discounts and rebates on the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company arranges with certain commercial and government entities allowing them to buy products directly from wholesalers at specific prices. These entities purchase products through wholesalers at the discounted price, and the wholesalers charge the difference between their list price and the discounted price back to the Company. The Company accrues estimated chargebacks based on estimated percentages of products sold to these entities, contract prices, and estimated levels of inventory in the distribution channel and records the chargebacks as a reduction of product revenues. Accrued chargebacks are recorded as an allowance against trade receivables on the consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Product Returns</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For some products, the Company's customers generally have the right to return product during the period beginning six months prior to the product expiration date and up to one year after the product expiration date. The Company does not have extensive history of product returns and uses various factors to estimate the provision for returns, including the launch date of products, third-party industry data for comparable products in the market and estimated channel inventory data. In a reporting period, the Company may decide to constrain revenue for product returns based on information from various sources, including channel inventory levels, inventory dating, prescription data, the expiration dates of product currently being shipped, price changes of competitive products and introductions of generic products. While the Company believes that the returns reserve is sufficient to avoid a significant reversal of revenue in future periods, if it were to increase or decrease the rate by 1%, it would have a $0.6 million impact on revenue in the year ended December 31, 2021. The Company records estimated product returns in accrued returns reserve on the consolidated balance sheets and as a reduction of product revenues.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Payment Discounts</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an incentive for prompt payment, the Company offers a discount to most customers. The Company expects that all eligible customers will comply with the contractual terms to earn the discount, and, therefore, the Company accrues the discount on all eligible sales. The Company records the discount as an allowance against trade accounts receivable on the consolidated balance sheets and as a reduction of product revenues.</span></div>
CY2021Q4	xers	A Change Of Returns Reserve Percentage AChangeOfReturnsReservePercentage	0.01
CY2021Q4	xers	Impact On Revenue If Returns Reserve Changed By1 ImpactOnRevenueIfReturnsReserveChangedBy1	600000	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of credit risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2021 and 2020, four customers accounted for 95% and 92% of the Company’s gross product revenues, respectively. The same four customers accounted for 99% and 98% of the trade accounts receivable, net at December 31, 2021 and December 31, 2020, respectively.</span></div>
CY2021	xers	Concentrationrisknumberofmajorcustomers Concentrationrisknumberofmajorcustomers	4
CY2021	xers	Concentration Risk Percentageof Gross Revenue ConcentrationRiskPercentageofGrossRevenue	0.95
CY2020	xers	Concentration Risk Percentageof Gross Revenue ConcentrationRiskPercentageofGrossRevenue	0.92
CY2021	xers	Concentrationrisknumberofmajorcustomers Concentrationrisknumberofmajorcustomers	4
CY2021	xers	Concentration Risk Percentageof Accounts Receivable ConcentrationRiskPercentageofAccountsReceivable	0.99
CY2020	xers	Concentration Risk Percentageof Accounts Receivable ConcentrationRiskPercentageofAccountsReceivable	0.98
CY2021	xers	Available For Sale Securities Maturities Period AvailableForSaleSecuritiesMaturitiesPeriod	P0Y6M
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	35169000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	9000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	35162000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	96159000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	36000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	96190000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5181000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2874000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7442000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	4247000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	5495000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1232000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	18118000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	8353000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1000000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2200000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	131450000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10762000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9258000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4135000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2551000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6627000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6707000	USD
CY2021	xers	Depreciation Depletionand Amortizationnotincludingassetimpairments DepreciationDepletionandAmortizationnotincludingassetimpairments	1300000	USD
CY2020	xers	Depreciation Depletionand Amortizationnotincludingassetimpairments DepreciationDepletionandAmortizationnotincludingassetimpairments	1500000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	132000000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	550000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	10843000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	10843000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	10843000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	10843000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	10293000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	77785000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	131450000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19638000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7989000	USD
CY2021Q4	xers	Accrued Supply Liabilities Current AccruedSupplyLiabilitiesCurrent	6009000	USD
CY2020Q4	xers	Accrued Supply Liabilities Current AccruedSupplyLiabilitiesCurrent	0	USD
CY2021Q4	xers	Accrued Supply Chain Costs AccruedSupplyChainCosts	595000	USD
CY2020Q4	xers	Accrued Supply Chain Costs AccruedSupplyChainCosts	1702000	USD
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3237000	USD
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	1114000	USD
CY2021Q4	xers	Accruedresearchcosts Accruedresearchcosts	1998000	USD
CY2020Q4	xers	Accruedresearchcosts Accruedresearchcosts	678000	USD
CY2021Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	6715000	USD
CY2020Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	811000	USD
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1413000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1527000	USD
CY2021Q4	xers	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	1839000	USD
CY2020Q4	xers	Accrued Transaction Costs Current AccruedTransactionCostsCurrent	0	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	7644000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2074000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	49088000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	15895000	USD
CY2020Q3	xers	Convertible Notes Purchased Due To Exercise Of Underwriter Option ConvertibleNotesPurchasedDueToExerciseOfUnderwriterOption	11300000	USD
	xers	Principal Amount Of Convertible Notes Converted PrincipalAmountOfConvertibleNotesConverted	8400000	USD
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2736591	shares
CY2020Q4	xers	Principal Amount Of Convertible Notes Converted Privately PrincipalAmountOfConvertibleNotesConvertedPrivately	30700000	USD
CY2020Q4	xers	Stock Issued During Period Shares Conversion Of Convertible Securities Privately Exchanged StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPrivatelyExchanged	10435200	shares
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	90675000	USD
CY2021	us-gaap	Interest Expense InterestExpense	7200000	USD
CY2020	us-gaap	Interest Expense InterestExpense	10700000	USD
CY2020	xers	Loss On The Convertible Note Exchange Transactions LossOnTheConvertibleNoteExchangeTransactions	2600000	USD
CY2021Q4	xers	Prepaymentallowedperdebtagreement Prepaymentallowedperdebtagreement	2000000	USD
CY2021	xers	Prepaymentpenaltypercentage Prepaymentpenaltypercentage	0.0150
CY2021Q4	xers	Finalpaymentfeepercentage Finalpaymentfeepercentage	0.030
CY2021Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2608000	USD
CY2020Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3654000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	88067000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	87021000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Two LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo	29000000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Three LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree	14500000	USD
CY2021Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Four LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour	47175000	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4540437	shares
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	67271000	USD
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	35162000	USD
CY2021Q4	us-gaap	Contingent Consideration Classified As Equity Fair Value Disclosure ContingentConsiderationClassifiedAsEquityFairValueDisclosure	22531000	USD
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1769000	USD
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	37598000	USD
CY2020Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	96190000	USD
CY2020Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	159000	USD
CY2020Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	159000	USD
CY2021	xers	Class Of Warrant Or Right Warrants Assumed ClassOfWarrantOrRightWarrantsAssumed	908000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	702000	USD
CY2021Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1769000	USD
CY2021Q4	xers	Total Common Stock And Preferred Stock Authorized Shares TotalCommonStockAndPreferredStockAuthorizedShares	375000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10299769	shares
CY2020Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.15
CY2020Q1	xers	Commonsharesissuedduetoexerciseofunderwriteroption Commonsharesissuedduetoexerciseofunderwriteroption	1299769	shares
CY2020Q1	xers	Netproceedsfromissuanceofpublicoffering Netproceedsfromissuanceofpublicoffering	39900000	USD
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8510000	shares
CY2020Q3	xers	Netproceedsfromissuanceofpublicoffering Netproceedsfromissuanceofpublicoffering	21600000	USD
	xers	Principal Amount Of Convertible Notes Converted PrincipalAmountOfConvertibleNotesConverted	8400000	USD
CY2020Q3	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.72
CY2020Q3	xers	Commonsharesissuedduetoexerciseofunderwriteroption Commonsharesissuedduetoexerciseofunderwriteroption	1110000	shares
	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	2736591	shares
CY2020Q4	xers	Principal Amount Of Convertible Notes Converted Privately PrincipalAmountOfConvertibleNotesConvertedPrivately	30700000	USD
CY2020Q4	xers	Stock Issued During Period Shares Conversion Of Convertible Securities Privately Exchanged StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesPrivatelyExchanged	10435200	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6553398	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6553398	shares
CY2021Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	4.12
CY2021Q1	xers	Netproceedsfromissuanceofpublicoffering Netproceedsfromissuanceofpublicoffering	26900000	USD
CY2021	xers	Restricted Stock Units Vested And Settled During Period RestrictedStockUnitsVestedAndSettledDuringPeriod	458416	shares
CY2021	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	141644	shares
CY2021	xers	Statutory Withholding Taxes On Vesting And Settlement Of Rs Us StatutoryWithholdingTaxesOnVestingAndSettlementOfRSUs	500000	USD
CY2020	xers	Restricted Stock Units Vested And Settled During Period RestrictedStockUnitsVestedAndSettledDuringPeriod	31250	shares
CY2020	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	9801	shares
CY2020	xers	Statutory Withholding Taxes On Vesting And Settlement Of Rs Us StatutoryWithholdingTaxesOnVestingAndSettlementOfRSUs	100000	USD
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	93399	shares
CY2021	xers	Leastamountofannualincreaseofsharesavailableforissuance Leastamountofannualincreaseofsharesavailableforissuance	386000	shares
CY2020Q4	xers	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Upon Option Exchange ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodUponOptionExchange	832907	shares
CY2020Q4	xers	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Upon Option Exchange ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledUponOptionExchange	-1127906	shares
CY2020Q4	xers	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Upon Option Exchange Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodUponOptionExchangeWeightedAverageExercisePrice	4.09
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4953906	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.84
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y5M15D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	741613	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.86
CY2021	xers	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Upon Option Exchange ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriodUponOptionExchange	6400246	shares
CY2021	xers	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Upon Option Exchange Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodUponOptionExchangeWeightedAverageExercisePrice	6.17
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.14
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	411080	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.31
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	228950	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	11.42
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	11362336	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.86
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M13D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	9645482	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.94
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M4D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	11362336	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.86
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y7M13D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	7.07
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.62
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	6.29
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	4.94
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	5.15
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11381000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8273000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	11741000	USD
CY2021	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000	USD
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000	USD
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Cash Awards Granted Percentage DeferredCompensationArrangementWithIndividualCashAwardsGrantedPercentage	1
CY2021	xers	Deferred Compensation Accrued Interest Rate DeferredCompensationAccruedInterestRate	0.02
CY2021	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	1600000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1813000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2031000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1981000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1931000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1982000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	21479000	USD
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2400000	USD
CY2020	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2300000	USD
CY2021Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	1400000	USD
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	35157496	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	21231135	shares
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-25772000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-19162000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4422000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-4375000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-350000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-480000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	302000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	16000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1779000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	710000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	901000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	1014000	USD
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-2450000	USD
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-1203000	USD
CY2021	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	663000	USD
CY2020	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	0	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	29642000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	23543000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	311000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-141000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-110000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	100790000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	74894000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7184000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	8362000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3177000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1894000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	27094000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	7785000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	137881000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	92493000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	364000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	442000	USD
CY2021Q4	xers	Deferred Tax Liabilities Fixedand Intangible Assets DeferredTaxLiabilitiesFixedandIntangibleAssets	197000	USD
CY2020Q4	xers	Deferred Tax Liabilities Fixedand Intangible Assets DeferredTaxLiabilitiesFixedandIntangibleAssets	404000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	5109000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	38000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5306000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	442000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4942000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	475700000	USD
CY2021Q4	xers	Operatinglosscarryforwardsvariousstates Operatinglosscarryforwardsvariousstates	309700000	USD
CY2020Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	284800000	USD
CY2020Q4	xers	Operatinglosscarryforwardsvariousstates Operatinglosscarryforwardsvariousstates	220600000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.80
CY2021Q4	xers	Federalresearchincometaxcreditsgrossofvaluationallowance Federalresearchincometaxcreditsgrossofvaluationallowance	5400000	USD
CY2021Q4	xers	Stateresearchincometaxcreditsgrossofvaluationallowance Stateresearchincometaxcreditsgrossofvaluationallowance	2500000	USD
CY2020Q4	xers	Federalresearchincometaxcreditsgrossofvaluationallowance Federalresearchincometaxcreditsgrossofvaluationallowance	8000000	USD
CY2020Q4	xers	Stateresearchincometaxcreditsgrossofvaluationallowance Stateresearchincometaxcreditsgrossofvaluationallowance	1700000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	68950000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-23543000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	92493000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-45388000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	137881000	USD
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	929000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	945000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	17000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	48000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	319000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	64000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	627000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	929000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	600000	USD
CY2020	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	USD
CY2021	dei	Auditor Firm AuditorFirmId	185

Files In Submission

Name	View Source	Status
0001867096-22-000040-index-headers.html	Edgar Link	pending
0001867096-22-000040-index.html	Edgar Link	pending
0001867096-22-000040.txt	Edgar Link	pending
0001867096-22-000040-xbrl.zip	Edgar Link	pending
a202110-kexhibit231.htm	Edgar Link	pending
a202110-kexhibit311.htm	Edgar Link	pending
a202110-kexhibit312.htm	Edgar Link	pending
a202110-kexhibit321.htm	Edgar Link	pending
a202110-kexhibit322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
xeris-ex211xlistofsubsidia.htm	Edgar Link	pending
xeris-ex43xdescriptionofse.htm	Edgar Link	pending
xers-20211231.htm	Edgar Link	pending
xers-20211231.xsd	Edgar Link	pending
xers-20211231_cal.xml	Edgar Link	unprocessable
xers-20211231_def.xml	Edgar Link	unprocessable
xers-20211231_g1.jpg	Edgar Link	pending
xers-20211231_g2.jpg	Edgar Link	pending
xers-20211231_htm.xml	Edgar Link	completed
xers-20211231_lab.xml	Edgar Link	unprocessable
xers-20211231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$XERS
Xeris Biopharma Holdings, Inc. Stock $xers

2021 Q4 Form 10-K Financial Statement

#000186709622000040 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERS Xeris Biopharma Holdings, Inc. Stock $xers

2021 Q4 Form 10-K Financial Statement

#000186709622000040 Filed on March 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$XERS
Xeris Biopharma Holdings, Inc. Stock $xers